References
- Organization WH, Coronavirus disease 2019 ( COVID-19): situation report, 88; 2020.
- Jordan RE, Adab P, Cheng K. Covid-19: risk factors for severe disease and death. British Medical Journal Publishing Group; 2020;368:m1198. Published 2020 Mar 26. doi:10.1136/bmj.m1198.
- Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University; 2020 [accessed 2020 April 9].
- Tadic M, Cuspidi C, Mancia G, Dell’Oro R, Grassi G. COVID-19, hypertension and cardiovascular diseases: should we change the therapy? Pharmacol Res. 2020;158:104906.
- Emami A, Javanmardi F, Akbari A, Moghadami M, Bakhtiari H, Falahati F, Hashemi Zadeh Fard Haghighi L, Rezaei T. Characteristics of deceased patients with CoVID-19 after the first peak of the epidemic in Fars province, Iran. Infect Ecol Epidemiol. 2020;10(1):p. 1781330.doi:10.1080/20008686.2020.1781330.
- Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis. 2020;94:44–48.
- Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emer Med. 2020;8(1):e35.
- Thomson G. COVID‐19: social distancing, ACE 2 receptors, protease inhibitors and beyond? Int J Clin Pract. 2020;74. doi:10.1111/ijcp.13503.
- Gandomkar A, et al. Prevalence, awareness, treatment, control, and correlates of hypertension in the pars cohort study. Arch Iran Med. 2018;21:p. 335–343.
- Fang L, Karakiulakis G, Roth M.Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020;8(4):e21.
- Nadar SK, Tayebjee MH, Stowasser M, Byrd JB. Managing hypertension during the COVID-19 pandemic. J Hum Hypertens. 2020;34(6):415–417. doi:10.1038/s41371-020-0356-y.
- Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis. Rev Med Virol. 2020;30(4):e2112. doi:10.1002/rmv.2112
- Devaux CA, Rolain J-M, Raoult D.ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53(3):425–35.doi:10.1016/j.jmii.2020.04.015.
- Zhang J, Wu J, Sun X, Xue H, Shao J, Cai W, Jing Y, Yue M, Dong C. Association of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. Epidemiol Infect. 2020;148. doi:10.1017/S095026882000117X.
- Furuhashi M, Moniwa N, Takizawa H, Ura N, Shimamoto K. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19. Hyper Res. 2020;43(8):837–840. doi:10.1038/s41440-020-0478-1.
- Zhang P, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671–1681. doi:10.1161/CIRCRESAHA.120.317134.
- Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin–angiotensin system inhibitors. Clin Exp Hypertens. 2020;;42(7):656-660. doi:10.1080/10641963.2020.1764018.
- Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, Tan J, Xu Y, Song R, Song M. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. MedRxiv. 2020.